Hypertrophic osteoarthropathy pathogenesis: a case highlighting the potential role for cyclo-oxygenase-2-derived prostaglandin E2.

Kozak KR, Milne GL, Morrow JD, Cuiffo BP
Nat Clin Pract Rheumatol. 2006 2 (8): 452-6; quiz following 456

PMID: 16932737 · DOI:10.1038/ncprheum0252

BACKGROUND - A 65-year-old woman presented with weakness, 9 kg weight loss, dysphagia, facial and bilateral upper-extremity swelling, and debilitating, bilateral lower-extremity pain. The patient had undergone a right upper lobectomy for a 5 mm, poorly differentiated adenocarcinoma of the lung 4 years previously. Medical history included chronic obstructive pulmonary disease (emphysema), hypertension, cerebrovascular disease and multinodular goiter. Surgical history included a right carotid endarterectomy. The patient's history was remarkable for 50+ pack-years of smoking.

INVESTIGATIONS - Physical examination, comprehensive metabolic panel and complete blood counts, CT, bone scintigraphy, quantification of urinary 11a-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (also known as PGE-M).

DIAGNOSIS - Recurrent non-small-cell lung cancer with adrenal metastasis, hypertrophic osteoarthropathy associated with non-small-cell lung cancer, and hyperprostaglandinuria.

MANAGEMENT - Rofecoxib 25 mg daily for hypertrophic osteoarthropathy, palliative external-beam radiation (44 Gy in 22 fractions) for mediastinal mass, palliative external-beam radiation (30 Gy in 12 fractions), followed 2 years later with radiofrequency ablation, for left adrenal metastasis.

MeSH Terms (13)

Aged Carcinoma, Non-Small-Cell Lung Cyclooxygenase 2 Cyclooxygenase 2 Inhibitors Dinoprostone Fatal Outcome Female Humans Lactones Lung Neoplasms Membrane Proteins Osteoarthropathy, Secondary Hypertrophic Sulfones

Connections (2)

This publication is referenced by other Labnodes entities: